CervoMed appoints Matthew Winton as chief commercial and business officer

BOSTON - CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders with a market capitalization of approximately $80 million, announced Tuesday the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 8.2x, according to InvestingPro data.

Winton brings nearly two decades of biotechnology industry experience to the company as it advances its lead candidate neflamapimod into Phase 3 development for dementia with Lewy bodies (DLB). The appointment comes at a crucial time as InvestingPro analysis shows analysts have recently revised their earnings expectations downward, with revenue projected to decline this year.

"This appointment comes at a pivotal time for CervoMed as we advance into late-stage Phase 3 development," said John Alam, M.D., Chief Executive Officer of CervoMed, in a press release statement.

Prior to joining CervoMed, Winton served as Chief Operating Officer at Inozyme Pharma, which was recently acquired by BioMarin Pharmaceuticals. He previously spent nearly a decade at Biogen in senior leadership roles, including Senior Vice President and Head of the U.S. Multiple Sclerosis Franchise and Vice President and Head of the U.S. Spinal Muscular Atrophy Franchise.

At Biogen, Winton managed multi-billion-dollar neurology portfolios and guided the launch of SPINRAZA, the first approved treatment for spinal muscular atrophy.

Winton holds a Ph.D. in Neuroscience from the Université de Montreal, an M.B.A. in Health Sector Management from Boston University, and completed his postdoctoral fellowship at the University of Pennsylvania's Center for Neurodegenerative Disease Research.

As part of his employment agreement, CervoMed granted Winton an option on October 6 to purchase 75,000 shares of company common stock with an exercise price of $8.62, vesting over three years. The stock, which has shown strong year-to-date returns of over 268%, currently trades near its InvestingPro Fair Value. Investors seeking deeper insights into CervoMed's financial health and growth prospects can access additional analysis and 8 more exclusive ProTips on InvestingPro.

In other recent news, CervoMed Inc. has reported positive results from its RewinD-LB trial, which showed that their experimental drug neflamapimod significantly slowed clinical progression in patients with dementia with Lewy bodies. The trial data revealed a 54% reduction in the risk of clinically significant worsening, with an improvement to 64% among patients with minimal Alzheimer's Disease co-pathology. Following these promising results, Canaccord Genuity raised its price target for CervoMed to $27 from $21, citing improved approval odds for neflamapimod based on encouraging 32-week open-label extension data. Similarly, D. Boral Capital increased its price target for the company from $10 to $15, maintaining a Buy rating and highlighting a strengthened translational link between drug exposure and clinical benefits. CervoMed plans to discuss these findings further during a conference call, coinciding with presentations at the Alzheimer's Association International Conference 2025. These developments have sparked interest among investors and analysts, reflecting optimism about the drug's potential impact on dementia treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.